Shares of Galera Therapeutics Inc. (GRTX) skyrocketed 95% on Tuesday, thanks to corrected results from its ROMAN trial.The ROMAN trial is a phase III study comparing the company's lead drug candidate Avasopasem against placebo for the treatment of severe oral mucositis in patients with locally advanced head and neck cancer undergoing standard-of-care radiotherapy.Avasopasem, also known as GC4419, ...
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.